CAHR is excited to announce that this meeting will be delivered on a new and exciting technological platform, to provide an interactive and user-friendly experience.

Virtual conference participants will enjoy all the activities that make the CAHR Conference an engaging learning experience including plenary sessions; special sessions on a wide variety of topics; oral abstracts and poster viewings; and opportunities to converse and network with colleagues and friends. The agenda and format are under development, and the CAHR website will be updated regularly as additional information becomes available.

Gay, bisexual and other men who have sex with men (MSM) have been disproportionally affected by the HIV epidemic in British Columbia (BC). Since 2010, Treatment as Prevention®¨ (TasP®¨) has been adopted as a public health policy in BC to maximize health care engagement of people living with HIV and improve virologic suppression, and as a result, to reduce secondary new infections. However, TasP®¨ has been relatively less responsive in reducing HIV transmission among MSM than in other populations in BC, which calls for further optimization and combination with other preventive strategies.

The BC-CfE’s Laboratory Director Dr. Zabrina Brumme alongside Dr. Mark Brockman of Simon Fraser University and Dr. Marc Romney of Providence Health Care and UBC co-led research which found that a single dose of the Pfizer-BioNTech COVID-19 vaccine produces a much weaker antibody response inlong-term care (LTC) residents than it does in younger healthy adults.

The BC-CfE’s Dr. Kate Salters, a research scientist with the Centre’s Epidemiology and Population Health program, along with BC-CfE Senior Scientist Dr. Robert Hogg, recently published research investigating mortality among under-served people living with HIV in BC.